PATENT 1646

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Guo et al.

Application No.: 09/933,780

Filed: August 21, 2001

Title: MEMBRANE PENETRATING PEPTIDES

AND USES

Examiner:

Unknown

Art Unit:

1646

PECEIVEL 2 2003 POOL 2 2003 I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop Commissioner of Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

 \boxtimes

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

]	(b)	This	s Information Disclosure Statement is filed after the period set forth in 37 C.F.R.
		1.97	(b), but is believed to be filed before the mailing date of a final action under §1.113
		or a	notice of allowance under §1.311, whichever occurs first.
		(1)	The undersigned attorney certifies that each item of information contained in this
			Information Disclosure Statement was cited in a communication from a foreign
			patent office in a counterpart foreign application not more than three months prior
			to the filing of this statement;
		(2)	The undersigned attorney certifies that no item of information contained in this
			Information Disclosure Statement was cited in a communication from a foreign
			patent office in a counterpart foreign application or, to the knowledge of the
			undersigned attorney after making reasonable inquiry, was known to any
			individual designated in §1.56(c) more than three months prior to the filing of this
			statement; or
		(3)	This Information Disclosure Statement is accompanied by a transmittal letter in
			which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is
			authorized.
			Respectfully subplitted, William C. Coppola, Reg. No. 41,686
			77 main C. Coppea, 106, 110, 41,000

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3800
Telefax (908) 231-2626

Aventis Docket No. HMR2053USNP1

Ļ	type a plus sign (+) inside this box →	1

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT


Co	omplete if Known	
Application Number	09/933,780	7
Filing Date	08-21-2001	
First Named Inventor	GUO	1/1
Group Art Unit	1646	2
Examiner Name	Unknown	M.
Attorney Docket Number	USHMR2053 - US - NP - 1	10

1	NIFORMATION DISCLOSURE				Application	n Number	09/93	33,780	k	
\$\\ \						Filing Date)	08-2	1-2001	
II S	STATEMENT BY APPLICANT				First Name	ed Inventor	GUC			
1	(use as many sheets as necessary)					Group Art L	Jnit	1646		
ž/	(ase as many shoots as necessary)					Examiner N	lame	Unkr	nown	
She	et	1	of		2	Attorney Do	cket Number	USH	IMR2053 - US - NP - 1	1000
_					II C DAT	ENT DOCUM	AENTS			200
_		U.S. Patent	Docum	cent I	U.S. PA1	ENT DOCUM			Pages, Columns, Lines,	20
Examiner Initials	Cite No.1	Number		Code ²	Name of Patentee of Cited Docu		Date of Publication Cited Docume MM-DD-YYY	ent	Where Relevant Passages or Relevant Figures Appear	90
	<u></u>							+		
 								_		
								#		
		<u> </u>		\vdash				+		•
								#		
-	-			\vdash			· · · · · · · · · · · · · · · · · · ·			
								\Box		
				\vdash				+		
								-		
	,	1					<u> </u>			

				FOR	EIGN PATENT DOCUMEN	rs		
Examiner Initials*	Cite No.1	Office ³	Foreign Patent Do	Cument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
		wo	01/38547	ĺ	Rosenecker et al.	05-31-2001		
		wo	01/93836		Boulikas	12-13-2001		
		wo	98/49325		Stochaj	11-05-1998		
		wo	99/49060		Lobie et al.	09-30-1999		
		wo	99/57138		Nadler	11-11-1999		+

Examiner	Date	
Signature	Considered	

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

•		_
Please type	a plus sign (+) inside this box $ ightharpoonup$	1

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ler the Paner	work R			no persons ar	e required to res	Patent and Trader	proved for use through 10/31/99. ON nark Office: U.S. DEPARTMENT OF ion unless it contains a valid OMB co	COMMERC	E I	
				no persons a	e required to res		omplete if Known		CV TO TO	
Substitu	te for i	orm 1449B/P	710			Application Number	09/933,780		一つ)_
INF	DRI	MATIC)ND	ISCLO	SURE		08-21-2001	166 16	を	Q.
AT2	TE	MENT	BV	ADDI I	CANT	First Named Inventor	GUO	Ch	ጌ ነ	1
\ 317		MITTIAL	TION DISCLOSURE INT BY APPLICANT Semany sheets as necessary) Of 2 Attorne OTHER PRIOR ART — NON PAT Include name of the author (in CAPITAL LETTER item (book, magazine, journal, serial, symposium, conceptible publisher, city and/or conceptible Research, Vol. 56, No. 5, Nov. 2000, pages ives et al., A Truncated HIV-1 TAT Protein Basic Inbrane And Accumulates In the Cell Nucleus, Journal of Biological Processor (Conceptible Research) Other Prior ART — NON PAT Include name of the author (in CAPITAL LETTER item (book, magazine, journal, serial, symposium, conceptible Research, Vol. 56, No. 5, Nov. 2000, pages ives et al., A Truncated HIV-1 TAT Protein Basic Inbrane And Accumulates In the Cell Nucleus, Journal of Biological Processor (Conceptible Research) Other Prior ART — NON PAT Include name of the author (in CAPITAL LETTER item (book, magazine, journal, serial, symposium, conceptible Research, Vol. 56, No. 5, Nov. 2000, pages item (book, magazine, journal, serial, symposium, conceptible Research, Vol. 56, No. 5, Nov. 2000, pages item (book, magazine, journal, serial, symposium, conceptible Research, Vol. 56, No. 5, Nov. 2000, pages item (book, magazine, journal, serial, symposium, conceptible Research, Vol. 56, No. 5, Nov. 2000, pages item (book, magazine, journal, serial, symposium, conceptible Research, Vol. 56, No. 5, Nov. 2000, pages item (book, magazine, journal, serial, symposium, conceptible Research, Vol. 56, No. 5, Nov. 2000, pages item (book, magazine, journal, serial, symposium, conceptible Research, Vol. 56, No. 5, Nov. 2000, pages item (book, magazine, journal, serial, symposium, conceptible Research, Vol. 56, No. 5, Nov. 2000, pages item (book, magazine, journal, serial, symposium, conceptible Research, Vol. 56, No. 5, Nov. 2000, pages item (book, magazine, journal, serial, symposium, conceptible Research, Vol. 56, No. 5, Nov. 2000, pages item (book, magazine, journal, serial, symposium, conceptible Research, Vol. 56, No. 5, Nov. 2000, pages item (book, magazine, journal, serial, symposium,	Group Art Unit	1646	1/3	T-2.	N		
.]	lu	MATION DISCLOSURE MENT BY APPLICANT (see as many sheets as necessary) Medication Notes that the property of		Examiner Name	Unknown	1	516	. `		
Sheet						Attorney Docket Number	USHMR2053 - US - NP -		7 5)
Officer			<u> </u>				00111111112000 00 111	·	200	
									~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	
	_						RE DOCUMENTS		-1 9	,
Examiner Initials*	Cite No.1				ımal, serial, sym	posium, catalog, etc.), date, pa	ge(s), volume-issue number(s),		T2	
							Polycationic Homopolymers, Jo	oumal		
		Membrane	And A	ccumulates Ir						
		M. Lindgre Vol. 21, No	en et al., o. 3, Ma	Cell-Penetra rch 2000, pa	ating Peptides, ges 99-103	, Trends in Pharmacological	Sciences, Elsevier Trends Jour	nal,		
				ginine-rich Po	eptides, Journ	al of Biological Chemistry, \	/ol. 276, No. 8, Nov. 17, 2000, p	ages		
							lly Active Protein into the Mouse	,		
		<del></del>								
									1	
···-					·				_	
									4	
	ļ									

Date

Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

~						
Please type	a plus	sign (+)	inside	this box	→	>

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

#### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

l pond to a col	Patent and Tradem	ank Office: U	e through 10/31/99. OMB 06 I.S. DEPARTMENT OF COM contains a valid OMB control	51-0031	<b>T</b>	
			f Known	3	2	
Applicat	ion Number	09/933,	780	2 4	CA'	
Filing Da	ate	08-21-2	001	<b>7</b>		
First Na	med Inventor	GUO		1	2 7	7
Group Ar	t Unit	1646			کے ل	Ũ
Examine	r Name	Unknow	'n	73	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	Ź
Attorney I	Docket Number	USHMR	2053 - US - NP - 1		E T	
NT DOC	JMENTS				TO	
Applicant nent	Date of Publicat Cited Docume MM-DD-YYY	ent	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			

U.S. PATENT DOCUMENTS										
Examiner	Cite	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines,				
Initials*	No.1	Number	Kind Code ² (if known)	of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear				
			<del></del>	<del></del>						
+										
<del></del> +	-									
<del></del> -⊦										
<del></del> -	-									
			-++							
	I									

ļ				FOR	EIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No.1	Office	Foreign Patent Do  Number ⁴		Name of Patentee or	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant	Т6
		WO	01/38547		Rosenecker et al.	05-31-2001	Figures Appear	┿
		wo	01/93836		Boulikas	12-13-2001		+
		wo	98/49325		Stochaj	11-05-1998		+-
		wo	99/49060		Lobie et al.	09-30-1999		1—
		wo	99/57138		Nadler	11-11-1999		
						+		+

Examiner	Date	
Signature	Considered	
	Contolacica	ĺ

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type	а	plus	sign	(+9	inside	this box	<b>→</b>	

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

Examiner

Signature

# **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2


Complete if Known					
Application Number	09/933,780				
Filing Date	08-21-2001	3 1			
First Named Inventor	GUO	C			
Group Art Unit	1646	7			
Examiner Name	Unknown	7			
Attorney Docket Number	USHMR2053 - US - NP - 1	7			

		OTHER PRIOR ART. MAN PATELLE THE ATTENDANCE OF THE PARENT.	~
		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		D.J. Mitchell et al., Polyarginine Enters Cells More Efficiently Than Other Polycationic Homopolymers, Journal of Peptide Research, Vol. 56, No. 5, Nov. 2000, pages 318-325	
		E. Vives et al., A Truncated HIV-1 TAT Protein Basic Domain Rapidly Translocates Through The Plasma Membrane And Accumulates In the Cell Nucleus, Journ. of Biological Chemistry, Vol. 22, No. 25, June 20 1997, pages 16010-16017	
		M. Lindgren et al., Cell-Penetrating Peptides, Trends in Pharmacological Sciences, Elsevier Trends Journal, Vol. 21, No. 3, March 2000, pages 99-103	
		S. Futaki et al., Arginine-rich Peptides, Journal of Biological Chemistry, Vol. 276, No. 8, Nov. 17, 2000, pages 5836-5840	
		S. Schwarze et al., In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse, Science, Vol. 285, Sept. 3, 1999, pages 1569-1572	
_			

Date

Considered

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.